<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585894</url>
  </required_header>
  <id_info>
    <org_study_id>H-18008313</org_study_id>
    <nct_id>NCT03585894</nct_id>
  </id_info>
  <brief_title>The Role of Inflammation and Vasodilatation in PACAP38-induced Headache Using MRI on Healthy Subjects</brief_title>
  <official_title>The Role of Inflammation and Vasodilatation in PACAP38-induced Headache Using MRI on Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studying Pituitary adenylate cyclase-activating peptide 38 (PACAP38) induced headache effects
      on extra- and intracerebral arteries and pre-posttreated by sumatriptan and ketorolac
      assessed by magnetic resonance imaging (MRI) on healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research project is to investigate the importance of blood vessel
      (vasodilatation), vessel wall inflammation and blood flow in arteries of headaches triggered
      by PACAP38 and for headache treated with sumatriptan (migraine medicine) and ketorolac
      (NSAID). In addition, we will investigate headache-related changes in the brain's network
      connectivity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">November 25, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each participant will receive PACAP28 intravenous infusion over 20 min in both experiment days but treated in randomized order with sumatriptan or ketorolac.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-extra cerebral arteries vasodilatation</measure>
    <time_frame>120 minutes</time_frame>
    <description>PACAP38 vasodilatation reverse by sumatriptan but not ketorolac. A single-slab 3D time-of-flight (3D TOF) MRA of extra- and intracranial arteries will be acquired as described in previous studies (Amin et al., 2013, 2014). MRA data will be analyzed by LKEB-MRA vessel wall analysis software program. We will measure the circumference of vessels in millimeter in 4 predefined time points (0, 20, 60 and 110 min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Headache score</measure>
    <time_frame>6 hours</time_frame>
    <description>Visual analog Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 hours</time_frame>
    <description>vital parameters recorded at hospital phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache characteristics</measure>
    <time_frame>24 hours</time_frame>
    <description>Standard headache questionnaire will be used to record headache localization, nausea, photo and phonophobia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>2 hours</time_frame>
    <description>vital parameters recorded at hospital phase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Sumatriptan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sumatriptan 4 mg/mL I.V will be administrated over 10 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketorolac 30 mg/mL I.V will be administrated over 10 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sumatriptan</intervention_name>
    <description>Receive intravenous infusion of sumatriptan</description>
    <arm_group_label>Sumatriptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Receive intravenous infusion of ketorolac</description>
    <arm_group_label>Ketorolac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Aged 18-50

          -  50-100 kg

        Exclusion Criteria:

          -  Tension type headache more than 5 dag /month

          -  Other primary headaches

          -  Daily medication except contraceptives

          -  Drug taken within 4 times the half-life for the specific drug except contraceptives

          -  Pregnant or lactating women

          -  Exposure to radiation within the last year

          -  Headache within the last 24 hours before start of trial

          -  Hypertension

          -  Hypotension

          -  Respiratory or cardiac disease

          -  Primary relatives with current or previous migraine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>December 29, 2019</last_update_submitted>
  <last_update_submitted_qc>December 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Hashmat Ghanizada</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

